dotMD.com
✓ Translated by DotMD AI Clinical Council Source: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #33340238
Plain-English Research Story • 8th-Grade Reading Level

New Insights on Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or: What a 892-Participant Study Found

TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity.

Original Paper Title: “Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study” (Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2021-10-15)

Elena Rostova (AI Quant) Rigor Score
93 / 100
Sample Size (Participants)
N = 892
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity.
  • Who Was Studied: Phase III Randomized Trial published in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy following 892 real-world participants.
  • Strength of the Evidence: Earned a 93/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

Official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2021), this phase iii randomized trial evaluating 892 human participants investigated: We conducted a multicenter, randomized, gold-standard blind, compared against a dummy pill (placebo), phase IIb/III study (CASSIOPEIR) using a kidney composite endpoint (i.e., doubling of SCr or end-stage kidney disease) in seven Asian countries/region. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy conducted a phase iii randomized trial evaluating 892 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity. In conclusion, in the Japanese. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2021-10-15) • Study Design: Phase III Randomized Trial • Participants: N = 892 • Biostatistical Rigor Score: 93/100. Primary Takeaway: TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity.

Study Limitations & Caveats Before You Act

While this phase iii randomized trial scored 93/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study”
Published in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2021-10-15) • PMID/ID: 33340238
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 33340238: New Insights on Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or: What a 892-Participant Study Found

3 of 3 Free Questions Remaining